Neshima is developing treatments for severe lung diseases to improve patient outcomes and save lives. Our patented LiFT™ (Liquid Foam Therapy) platform uses non-Newtonian foam to improve respiratory drug delivery by orders of magnitude across several key delivery parameters compared with conventional delivery methods like nebulizers and intravenous delivery.

LiFT is designed to carry a wide range of therapeutics, from small molecules and biologics to cells. It can accommodate existing and emerging therapeutics while minimizing the need for complex reformulation for pulmonary delivery.

The foam is shear-thinning: its viscosity drops substantially as it passes through narrowed airways, helping it flow through obstructed airways and reach diseased lung regions.

We are developing LiFT for the treatment of severe pneumonia, COPD and lung cancer.

Neshima is a Technion spin-off backed by embARC Ventures (a joint venture of Sheba Medical Center, ARC and Ilex Medical), RS NESS, 8 other investors and R&D grants. 

Our technology is supported by peer-reviewed research and preclinical in vivo studies at human lung scale.